Which India-Produced COVID-19 is Best?

A non-peer-reviewed study published on April 13, 2021, assessed the humoral immune response after the first dose of two vaccines, Covishield and the BBV-152 (Covaxin), in 552 healthcare workers in India.

Both vaccines showed seropositivity to anti-spike antibodies 21 days or more after the first vaccine dose.

These researchers concluded this study by saying, 'While both vaccines elicited immune response, seropositivity rates to anti-spike antibody were significantly higher in Covishield recipient than Covaxin after the first dose.'

'The ongoing COVAT study will further enlighten the immune response between two vaccines after the second dose.'

Both of these COVID-19 vaccines are produced in India.